Antenatal administration of celecoxib, a selective cyclooxygenase (COX)-2 inhibitor, appears to improve placental perfusion in the pregnant rabbit

Prostaglandins and Other Lipid Mediators

Volumn 70, Issue 3-4, 2003, Pages 303-315

  Hausman, Nicole ^a,b   Beharry, Kay ^a   Nishihara, Kenji ^a   Akmal, Yasir ^a   Asrat, Tamerou ^a  

^a LONG BEACH MEMORIAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Fetal; Perfusion; Uteroplacental

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; NITRIC OXIDE; PROSTAGLANDIN E2; PROSTANOID; PROTEIN; THROMBOXANE B2;

ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BRAIN WEIGHT; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FETUS; FETUS GROWTH; GESTATION PERIOD; NONHUMAN; OXIDATION; PLACENTA PERFUSION; PLACENTA WEIGHT; PRENATAL PERIOD; RABBIT;

6-KETOPROSTAGLANDIN F1 ALPHA; ANIMALS; BODY WEIGHT; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; FEMALE; ISOENZYMES; NITRIC OXIDE; ORGAN SIZE; PERFUSION; PLACENTA; PREGNANCY; PREGNANCY, ANIMAL; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; PYRAZOLES; RABBITS; SULFONAMIDES; THROMBOXANE B2; TIME FACTORS;

EID: 0037229447     PISSN: 00906980     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-6980(02)00144-2     Document Type: Article

References (31)

1. Tuvemo T. Role of prostaglandins, prostacyclin, and thromboxanes in the control of the umbilical-placental circulation. Semin. Perinatol. 4:1980;91-95.
2. Magness R.R., Gant N.F. Control of vascular reactivity in pregnancy: the basis for therapeutic approaches to prevent pregnancy-induced hypertension. Semin. Perinatol. 18:1994;45-69.
3. Tanaka M., Natori M., Ishimoto H., Miyakoshi K., Miyazaki T., Kobayashi T.et al. Effects of a thromboxane synthetase inhibitor (OKY-046) in an ischemia-reperfusion model of intrauterine growth retardation in Sprague-Dawley rats. Biol. Neonate. 72:1997;181-186.
4. Goldin E., Harel S., Tomer A., Yavin E. Thromboxane and prostacyclin levels in fetal rabbit brain and placenta after intrauterine partial ischemic episodes. J. Neurochem. 54:1990;587-591.
5. Miller S.L., Jenkin G., Walker D.W. Effect of nitric oxide synthase inhibition on the uterine vasculature of the late-pregnant ewe. Am. J. Obstet. Gynecol. 180:1999;1138-1145.
6. Kublickiene K.R., Nisell H., Poston L., Kruger K., Lindblom B. Modulation of vascular tone by nitric oxide and endothelin 1 in myometrial resistance arteries from pregnant women at term. Am. J. Obstet. Gynecol. 182:2000;87-93.
7. Diket A.L., Pierce M.R., Munshi U.K., Voelker C.A., Eloby-Childress S., Greenberg S.S.et al. Nitric oxide inhibition causes intrauterine growth retardation and hind-limb disruptions in rats. Am. J. Obstet. Gynecol. 171:1994;1243-1250.
8. Gilroy D.W., Tomlinson A., Willoughby A. Differential effects of inhibition of isoforms of cyclooxygenase (COX-1, COX-2) in chronic inflammation. Inflamm. Res. 47:1998;79-85.
9. Zuo J., Lei Z.M., Rao C.V., Pietrantoni M., Cook V.D. Differential cyclooxygenase-1 and -2 gene expression in human myometria from preterm and term deliveries. J. Clin. Endocrinol. Metab. 79:1994;894-899.
10. Swaisgood C.M., Zu H.X., Perkins D.J., Wu S., Garver C.L., Zimmerman P.D.et al. Coordinate expression of inducible nitric oxide synthase and cyclooxygenase-2 genes in uterine tissues of endotoxin-treated pregnant mice. Am. J. Obstet. Gynecol. 177:1997;1253-1262.
11. 2 pathways in pregnant rat uteri. Am. J. Physiol. 270:1996;E471-E476.
12. Hawkey C.J. COX-2 inhibitors. The Lancet. 353:1999;307-314.
13. Powell W.S. Rapid extraction of arachidonic acid metabolites from biological samples using octadecylsilyl silica. Methods Enzymol. 86:1982;467-477.
14. Kajantie E., Hytinantti T., Koistinen R., Risteli J., Rutanen E.-M., Seppala M.et al. Markers of type I and type III collagen turnover, insulin-like growth factors, and their binding proteins in cord plasma of small premature infants: relationships with fetal growth, gestational age, preeclampsia, and antenatal glucocorticoid treatment. Pediatr. Res. 49:2001;481-489.
15. Hobbins J. Morphometry of fetal growth. Acta Paediatr. Suppl. 423:1997;165-168.
16. 18F ]fluorodopa positron emission tomographic study Pediatr. Res. 49:2001;474-480.
17. Garella S., Matarese R.A. Renal effects of prostaglandins and clinical adverse effects of nonsteroidal anti-inflammatory agents. Medicine. 63:1984;165-181.
18. Dunn M.J., Zambraski E.J. Renal effects of drugs that inhibit prostaglandin synthesis. Kidney Int. 18:1980;609-622.
19. Laudy J.A., Wladimiroff J.W. The fetal lung I: developmental aspects. Ultrasound Obstet. Gynecol. 16:2000;284-290.
20. Sorem K.A., Siler-Khodr T.M. Placental prostanoid release in severe intrauterine growth retardation. Placenta. 16:1995;503-515.
21. 2 induces its own secretion in vitro by bovine 270-day placenta but not by 200-day placenta. Prostaglandins. 57:1999;189-205.
22. Weiner C.P., Thompson L.P. Nitric oxide and pregnancy. Semin. Perinatol. 21:1997;367-380.
23. Brown M. The physiology of pre-eclampsia. Clin. Exp. Pharmacol. Physiol. 22:1995;781-791.
24. Sladek S.M., Magness R.R., Conrad K.P. Nitric oxide and pregnancy. Am. J. Physiol. 272:1997;R441-R463.
25. Cacciatore B., Halmesmaki E., Kaaja R., Teramo K., Ylikorkala O. Effects of transdermal nitroglycerin on impedance to flow in the uterine, umbilical, and fetal middle cerebral arteries in pregnancies complicated by preeclampsia and intrauterine growth retardation. Am. J. Obstet. Gynecol. 179:1998;140-145.
26. Smith G.C.S. The pharmacology of the ductus arteriosus. Pharmacol. Rev. 50:1998;35-58.
27. Demers L.M., Gabbe S.G. Placental prostaglandin levels in pre-eclampsia. Am. J. Obstet. Gynecol. 126:1976;137-139.
28. Fitzgerald G.A., Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. 345:2001;433-442.
29. Terragno N.A., Terragno D.A., Pacholczyk D., McGiff J.C. Prostaglandins and the regulation of uterine blood flow in pregnancy. Nature. 249:1974;57-58.
30. Romero R., Lockwood C., Oyarzun E., Hobbins J.C. Toxemia: new concepts in an old disease. Semin. Perinatol. 12:1988;302-323.
31. 2 in mononuclear cells from preeclamptic women. Am. J. Obstet. Gynecol. 169:1993;1106-1111.